Loading organizations...

Candel Therapeutics is a technology company.
Candel Therapeutics develops viral immunotherapies activating the immune system against cancer. The company utilizes genetically modified adenovirus and herpes simplex virus (HSV) constructs. These therapies induce in situ immunization, exposing tumor antigens and counteracting immunosuppressive microenvironment, fostering systemic anti-cancer immune responses.
Estuardo Aguilar-Cordova founded Candel Therapeutics in 2002. His insight focused on viral immunotherapies' dual mechanism: direct tumor destruction combined with robust immune stimulation. This approach overcomes traditional treatment limitations by educating a patient's immune system to recognize and combat cancer cells, driving personalized, durable therapeutic responses.
Candel Therapeutics focuses on patients with solid tumors like non-small cell lung and prostate cancer. The company's mission is to extend and improve lives through innovative viral immunotherapies. Their vision involves leveraging proprietary virus-based platforms to elicit potent immune responses against solid tumors and metastases, enhancing clinical outcomes.
Candel Therapeutics has raised $181.7M across 3 funding rounds.
Candel Therapeutics has raised $181.7M in total across 3 funding rounds.
Candel Therapeutics has raised $181.7M in total across 3 funding rounds.
Candel Therapeutics's investors include Robert Lake, Northpond Ventures, H7 Holdings, Level One Partners, Sands Capital, Paul Manning.
Candel Therapeutics is a clinical-stage biotechnology company developing viral-based immunotherapies for solid tumors, including prostate, brain, lung, and pancreatic cancers.[1][2][3] Its off-the-shelf multimodal biological immunotherapies aim to elicit individualized, systemic anti-tumor immune responses, helping patients fight cancer while preserving quality of life from early to late-stage disease.[1][2][3] The company, recently gone public under ticker $CADL and based in Needham, Massachusetts, maintains a robust pipeline with assets in Phase 1, 2, and 3 trials.[1][2]
Candel serves cancer patients by addressing unmet needs in solid tumor treatment through therapies that "light up and empower the immune system," producing patient-specific, long-lasting protection with favorable benefit-risk profiles.[3] Growth momentum includes its transition to public markets and active participation in biotech events like BIO International Convention 2025, signaling advancing clinical development.[2]
Candel Therapeutics emerged as a pioneer in viral immunotherapies, though specific founding details like exact year or founders are not detailed in available sources. The company has evolved into a newly public entity focused on clinical-stage assets for major solid tumors, building on expertise in off-the-shelf multimodal therapies that target individualized immune responses.[1][2] Pivotal moments include advancing a pipeline spanning Phase 1 to 3 trials and emphasizing patient-centric innovation, as highlighted in its commitment to team, patients, and community.[1][3] Its Massachusetts base aligns it with the state's strong biotech ecosystem, fostering early traction in immunotherapy R&D.[2]
Candel stands out in oncology through these key strengths:
Candel rides the wave of immunotherapy advancement in biotech, particularly viral vectors that harness the immune system for solid tumors, a segment where checkpoint inhibitors have shown limitations.[1][3] Timing is ideal amid rising demand for personalized, off-the-shelf biologics, fueled by market forces like aging populations, increasing cancer incidence, and post-pandemic focus on immune-modulating tech.[2] As a clinical-stage player in Massachusetts' biotech hub, Candel influences the ecosystem by contributing to MassBio and global conventions, accelerating R&D in multimodal therapies and bridging early discovery to late-stage trials.[1][2]
Candel's next milestones likely include Phase 3 readouts and potential approvals for lead assets in prostate or lung cancer, expanding its pipeline amid immunotherapy tailwinds.[1] Trends like AI-driven patient selection and combination regimens will shape its path, enhancing efficacy in hard-to-treat solids.[3] Its influence may grow as a public biotech leader in viral immunotherapies, potentially scaling impact through partnerships—echoing its mission to light up immune responses for transformative cancer care.[2][3]
Candel Therapeutics has raised $181.7M across 3 funding rounds. Most recently, it raised $130.0M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 19, 2025 | $130.0M Other Equity | Robert Lake | |
| Mar 1, 2019 | $23.0M Series C | Northpond Ventures | H7 Holdings, Level One Partners, Sands Capital |
| Jan 4, 2019 | $28.7M Series B | Paul Manning |